Diosmin
Research reviewed: Up until 03/2026
Diosmin is a dietary supplement with 10 published peer-reviewed studies involving 693 participants, researched for Venous Insufficiency, Haemorrhoids, Lymphedema and 2 more areas.
Evidence at a Glance
Strength is scored by study design, sample size, study type, and outcomes
Venous Insufficiency
StrongHaemorrhoids
ModerateLymphedema
ModerateVascular Protection
ModerateClinical trials
ModerateResearch Visualised
Visual breakdown of the clinical data.
Study Quality Breakdown
What types of studies were conducted
Participants Per Study
Larger samples = more reliable results
Research Timeline
When the studies were published
All Studies
Detailed breakdown of each trial. Click to expand.
Venous Insufficiency
To evaluate MPFF (Diosmin/Hesperidin) in chronic venous insufficiency
Study Type
Randomised double-blind placebo-controlled trial
Purpose
To evaluate MPFF (Diosmin/Hesperidin) in chronic venous insufficiency
Dose
Diosmin 900 mg + Hesperidin 100 mg twice daily
Participants
245 patients with CVI (CEAP C2-C4)
Duration
12 weeks
Results
MPFF significantly reduced leg heaviness, pain, cramps, and ankle circumference compared to placebo. Venous tone measured by duplex improved significantly in treatment group.
How They Measured It
CEAP classification, VAS pain, ankle circumference, duplex ultrasound
To evaluate the efficacy of MPFF in chronic venous disease
Study Type
Meta-analysis
Purpose
To evaluate the efficacy of MPFF in chronic venous disease
Dose
Diosmin 900 mg + Hesperidin 100 mg daily
Participants
Meta-analysis of 5 RCTs (n=1150)
Duration
Various
Results
MPFF consistently reduced CVD-related symptoms including leg pain, heaviness, and swelling. Meta-analysis demonstrated significant quality of life improvements and reduced symptom burden.
How They Measured It
RESTATE and RELIEF study data, symptom severity scores, quality of life
To evaluate Diosmin on venous ulcer healing as adjunct to compression therapy
Study Type
Randomised controlled trial
Purpose
To evaluate Diosmin on venous ulcer healing as adjunct to compression therapy
Dose
Diosmin 900 mg + Hesperidin 100 mg twice daily
Participants
120 patients with venous leg ulcers
Duration
24 weeks
Results
Addition of MPFF to compression therapy significantly increased ulcer healing rate (61% vs 48%) and accelerated time to complete healing. Largest benefit in ulcers present >6 months.
How They Measured It
Ulcer healing rate, wound area measurement, time to closure
Haemorrhoids
To assess MPFF for acute haemorrhoidal episodes
Study Type
Randomised double-blind placebo-controlled trial
Purpose
To assess MPFF for acute haemorrhoidal episodes
Dose
Diosmin 900 mg + Hesperidin 100 mg twice daily
Participants
140 patients with acute haemorrhoids
Duration
3 months
Results
MPFF significantly reduced bleeding, pain, and inflammatory signs and shortened the duration of acute attacks compared to placebo. Recurrence rate was also significantly lower at 3 months.
How They Measured It
Bleeding severity, pain scores, inflammatory signs, time to remission
To evaluate flavonoids including Diosmin for haemorrhoids
Study Type
Systematic review and meta-analysis
Purpose
To evaluate flavonoids including Diosmin for haemorrhoids
Dose
MPFF (Diosmin-based) formulations
Participants
Meta-analysis of 14 RCTs (n=1514)
Duration
Various
Results
Flavonoids significantly reduced risk of bleeding (RR 0.33), persistent pain (RR 0.65), itching (RR 0.35) and recurrence (RR 0.47). Diosmin-hesperidin combination was the most studied and effective formulation.
How They Measured It
Meta-analysis of RCTs; bleeding, prolapse, pruritus, overall symptom scores
Lymphedema
To evaluate MPFF for reduction of post-mastectomy arm lymphedema
Study Type
Randomised controlled trial
Purpose
To evaluate MPFF for reduction of post-mastectomy arm lymphedema
Dose
Diosmin 900 mg + Hesperidin 100 mg daily
Participants
57 women with post-mastectomy lymphedema
Duration
6 months
Results
MPFF significantly reduced arm circumference difference and limb volume compared to compression alone. Quality of life scores also significantly improved in the MPFF group.
How They Measured It
Arm circumference measurement, limb volume calculation, quality of life assessment
To investigate the lymphatico-venous mechanisms of Diosmin in experimental lymphedema
Study Type
Animal study
Purpose
To investigate the lymphatico-venous mechanisms of Diosmin in experimental lymphedema
Dose
100 mg/kg Diosmin
Participants
24 rats with experimental lymphedema
Duration
21 days
Results
Diosmin improved lymphatic vessel tone, enhanced lymph drainage, and significantly reduced edema volume. Proposed mechanism involves prostaglandin-mediated lymphatic smooth muscle tone regulation.
How They Measured It
Lymphatic vessel tone, edema volume, lymphocyte transport
Vascular Protection
To characterize vascular protective mechanisms of Diosmin at the endothelial level
Study Type
In vitro study
Purpose
To characterize vascular protective mechanisms of Diosmin at the endothelial level
Dose
Diosmin 10-100 μM
Participants
Human umbilical vein endothelial cells (HUVECs)
Duration
24 hours
Results
Diosmin significantly reduced endothelial permeability, suppressed ICAM-1 and VCAM-1 expression, and attenuated ROS production in TNF-α-stimulated endothelial cells.
How They Measured It
Endothelial permeability assay, adhesion molecule expression (ICAM-1, VCAM-1), ROS production
To evaluate Diosmin as adjunct therapy in diabetic peripheral neuropathy
Study Type
Randomised controlled trial
Purpose
To evaluate Diosmin as adjunct therapy in diabetic peripheral neuropathy
Dose
Diosmin 500 mg twice daily
Participants
88 patients with type 2 diabetes and peripheral neuropathy
Duration
16 weeks
Results
Diosmin significantly improved nerve conduction velocity and reduced neuropathy symptom scores. Oxidative stress markers and inflammatory cytokines also significantly reduced compared to control group.
How They Measured It
Nerve conduction velocity, neuropathy symptom score, oxidative stress markers
Clinical trials
To evaluate the efficacy and safety of diosmin in reducing lower-extremity swelling and pain after total knee arthroplasty (TKA).
Study Type
Randomized, controlled, multicenter trial
Purpose
To evaluate the efficacy and safety of diosmin in reducing lower-extremity swelling and pain after total knee arthroplasty (TKA).
Dose
0.9 g diosmin twice daily for 14 days
Participants
330 patients undergoing TKA across 13 university-affiliated hospitals
Duration
14 days
Results
Diosmin significantly reduced lower-extremity swelling and pain, improved HSS scores and range of knee motion, and reduced inflammatory markers compared to control.
How They Measured It
Lower-extremity circumference, VAS pain, HSS score, range of knee motion, inflammatory markers
Frequently Asked Questions
Common questions about Diosmin research
There are currently 10 peer-reviewed studies on Diosmin (Diosmin), involving 693 total participants. Research covers Venous insufficiency, Haemorrhoids, Lymphedema and 1 more areas. The overall evidence strength is rated as Strong.
The evidence is currently rated as "Strong Evidence". This rating is based on study design quality (randomisation, blinding, placebo controls), sample sizes, study types (6 human studies), and reported outcomes.
Diosmin has been researched for: Venous insufficiency, Haemorrhoids, Lymphedema, Vascular protection. Each area has its own body of evidence which you can explore in the study breakdowns above.
Yes, 6 out of 10 studies are human trials. Human trials carry more weight in our evidence scoring system.
Similar Supplements
Other supplements researched for similar health goals
